Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies
Jifa Zhang, Yinglu Zhang, Jiaxing Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 114
HDAC-targeting epigenetic modulators for cancer immunotherapy
Binbin Cheng, Wei Pan, Yao Xiao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116129-116129
Closed Access | Times Cited: 30
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 20
Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy
Liang Shen, Bo Wang, ShaoPeng Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 922-951
Closed Access | Times Cited: 16
Synthesis, biological evaluation and molecular docking studies of new pyrimidine derivatives as potent dual EGFR/HDAC inhibitors
G. Sivaiah, M.S. Raghu, S. Prasad, et al.
Journal of Molecular Structure (2024) Vol. 1309, pp. 138223-138223
Closed Access | Times Cited: 12
Degraders in epigenetic therapy: PROTACs and beyond
Xing‐Jie Dai, Shi‐Kun Ji, Meng‐Jie Fu, et al.
Theranostics (2024) Vol. 14, Iss. 4, pp. 1464-1499
Open Access | Times Cited: 11
Indole Derivatives: A Versatile Scaffold in Modern Drug Discovery—An Updated Review on Their Multifaceted Therapeutic Applications (2020–2024)
Xingyou Mo, Devendra Pratap Rao, Kirandeep Kaur, et al.
Molecules (2024) Vol. 29, Iss. 19, pp. 4770-4770
Open Access | Times Cited: 8
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 1
Acetyl-CoA metabolism as a therapeutic target for cancer
Guo Chen, Banghe Bao, Cheng Yang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115741-115741
Open Access | Times Cited: 18
Epigenetic regulation of tumor-immune symbiosis in glioma
Yang Liu, Heba Ali, Fatima Khan, et al.
Trends in Molecular Medicine (2024) Vol. 30, Iss. 5, pp. 429-442
Open Access | Times Cited: 6
Targeting histone deacetylase 6 (HDAC6) to enhance radiation therapy in meningiomas in a 2D and 3D in vitro study
Juri Na, Shahana Shaji, C. Oliver Hanemann
EBioMedicine (2024) Vol. 105, pp. 105211-105211
Open Access | Times Cited: 6
Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
Rui Han, Changquan Ling, Yuqian Wang, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Co‐delivery Nano System of MS‐275 and V‐9302 Induces Pyroptosis and Enhances Anti‐Tumor Immunity Against Uveal Melanoma
Hong Ren, Zhenkai Wu, Jia Tan, et al.
Advanced Science (2024) Vol. 11, Iss. 31
Open Access | Times Cited: 5
Epigenetic Modifications in Cancer Etiology, Diagnosis and Therapy
Tajudeen Yahaya, Emmanuel B. John, Asanka Sudeshini Hewage, et al.
Asian Journal of Biological Sciences (2025) Vol. 18, Iss. 2, pp. 516-532
Closed Access
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Ekta Shirbhate, Vaibhav Singh, Rakesh Kore, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
Epigenomic Echoes—Decoding Genomic and Epigenetic Instability to Distinguish Lung Cancer Types and Predict Relapse
Anke Baumann, Zholdas Buribayev, Olaf Wolkenhauer, et al.
Epigenomes (2025) Vol. 9, Iss. 1, pp. 5-5
Open Access
Exploring the oncogenic roles of T-box transcription factor TBX2 and its potential as a therapeutic target
Claire Bellis, Mihlali Mlaza, Abid Ali, et al.
Biochemical Society Transactions (2025) Vol. 53, Iss. 01
Closed Access
CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages
Xutao Xu, Qianqian Wang, Ke Guo, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Wound Healing Effect of HDACi Repositioned Molecules in the Therapy for Chronic Wounds Models
Alan Santos‐Mena, Oscar E. González-Muñiz, Adrián Rodríguez-Carlos, et al.
Experimental Dermatology (2025) Vol. 34, Iss. 2
Closed Access
Design, synthesis, and biological evaluation of novel artemisinin-based HDAC inhibitors with antitumor and antimalarial activities
Jin He, Youyou He, Yunan Qian, et al.
Bioorganic Chemistry (2025) Vol. 157, pp. 108312-108312
Closed Access
Epigenetic drugs in cancer therapy
Amila Suraweera, Kenneth J. O’Byrne, Derek J. Richard
Cancer and Metastasis Reviews (2025) Vol. 44, Iss. 1
Open Access
Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies
Jinshou Yang, Feihan Zhou, Xiyuan Luo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Synthesis and biological evaluation of the Fluoro analog of Romidepsin with improved selectivity for class I histone deacetylases (HDACs)
Xinluo Song, Hanqi Wang, Ya Gao, et al.
Bioorganic Chemistry (2025) Vol. 159, pp. 108348-108348
Closed Access
Decoding the Epigenome of Breast Cancer
Elisa Cortellesi, Isabella Savini, M Veneziano, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2605-2605
Open Access
Distribution, Metabolism, and Excretion of [14C] Purinostat Mesylate, a Novel Selective HDAC I/IIb Inhibitor, in Rats Analyzed by High-Performance Liquid Chromatography coupled with LTQ Orbitrap Mass Spectrometry/Radioactivity Monitoring
Ziyan Ma, Minghai Tang, Linyu Yang, et al.
Journal of Pharmaceutical and Biomedical Analysis (2025), pp. 116834-116834
Closed Access
Page 1 - Next Page

Scroll to top